© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
March 5 2021
ACCC Annual Conference
Lalan Wilfong, MD, an expert on value-based care, explains how Texas Oncology worked with physicians and payers to make biosimilars available for patients.
February 2 2021
Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.
Deana Ferreri, PhD
January 30 2021
Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).
January 21 2021
Annual J.P. Morgan Healthcare Conference
Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.
January 19 2021
The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.
January 18 2021
Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.
January 11 2021
Festival of Biologics Basel
Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.
January 9 2021
San Antonio Breast Cancer Symposium
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
January 4 2021
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
December 15 2020
In little over 1 year of use in patients with breast cancer, trastuzumab biosimilars have seen rapid growth in uptake.